Report: Ridgefield pharma sued for asthma inhaler doses

May 9, 2019

A Florida man has sued Boehringer Ingelheim Pharmaceuticals in Connecticut federal court, claiming the company failed to provide a promised number of doses in its Combivent Respimat inhalers that treat asthma.

Boehringer Ingelheim is based in Germany with its U.S. pharmaceutical headquarters in Ridgefield, where it is among the larger employers in the Danbury region. A company spokesperson did not respond immediately to a Hearst Connecticut Media query on the lawsuit, which was reported Tuesday by the Connecticut Law Tribune.

Plaintiff Carl Ignacuinos is seeking class-action status for his complaint, without stating a precise amount in damages he is seeking in the lawsuit but indicating it will likely exceed $5 million. In his lawsuit, Ignacuinos alleges Boehringer Ingelheim marketed some inhalers as having 120 doses, but that the devices in some cases had half that many.

Combivent is designed to treat chronic obstructive pulmonary disease by relaxing the lung’s muscles to improve breathing, through a regimen of four doses daily.

Alex.Soule@scni.com; 203-842-2545; @casoulman